Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Lorcaserin is a selective 5-HT2C (5-hydroxytryptamine 2C) receptor agonist indicated for weight management. Here, we assess the impact of lorcaserin on progression from prediabetes to type 2 diabetes (T2D) and on reversion from prediabetes to euglycemia. METHODS: This is a post hoc analysis of pooled data from two Phase 3 studies, BLOOM and BLOSSOM (N = 6136), evaluating the impact of lorcaserin on weight and glycemic parameters over 52 weeks in the subpopulation of obese/overweight subjects with prediabetes, alternately defined by fasting plasma glucose (FPG) 100-125 mg/dl or glycated hemoglobin (HbA1c) 5.7-6.4% at baseline. RESULTS: At Week 52, in the subpopulation with prediabetes, nearly twice as many lorcaserin-treated subjects achieved ≥5% weight loss versus placebo (HbA1c: 55.6% vs. 27.5%, p < 0.001; FPG: 52.8% vs. 28.8%, p < 0.001), and a significantly lower percentage of lorcaserin-treated subjects progressed to T2D versus placebo based on HbA1c (lorcaserin 3.2%, placebo 5.0%, p = 0.032) but not FPG (lorcaserin 1.6%, placebo 2.6%, p = 0.227). A significantly greater proportion of lorcaserin-treated subjects versus placebo also reverted to euglycemia based on both HbA1c (lorcaserin 40%, placebo 29.5%, p < 0.001) and FPG (lorcaserin 52.4%, placebo 46.5%, p = 0.047). CONCLUSION: In subjects with prediabetes, lorcaserin may contribute to weight loss and improve glycemic parameters, and thus may help with preventing progression to T2D and promoting reversion to euglycemia. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifiers are NCT00395135 (BLOOM) and NCT00603902 (BLOSSOM).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lorcaserin has also been reported to improve glycaemic control and induce weight loss in obese T2D subjects, and this drug was additionally shown to both reduce the risk of prediabetic individuals progressing to T2D and increase the likelihood of these subjects being able to revert to euglycemia.129,231”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [231]
In the citing paper
“Lorcaserin has also been reported to improve glycaemic control and induce weight loss in obese T2D subjects, and this drug was additionally shown to both reduce the risk of prediabetic individuals progressing to T2D and increase the likelihood of these subjects being able to revert to euglycemia.129,231”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [231]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Prevention Program (DPP) trials showed that moderate weight loss (5–7% of body weight) with lifestyle intervention programs reduced the incidence of T2D by 58%.[14,15] The DPP also showed that achieving euglycemia with weight loss significantly reduces cardiovascular risk (15.”
BackgroundTuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Prevention Program (DPP) trials showed that moderate weight loss (5–7% of body weight) with lifestyle intervention programs reduced the incidence of T2D by 58%.[14,15] The DPP also showed that achieving euglycemia with weight loss significantly reduces cardiovascular risk (15.”
BackgroundDanaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., Paciorek, C. J., Lin, J. K., Farzadfar, F., Khang, Y.-H., Stevens, G. A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60679-x · Cited by 3,568 · cited 1×
“than doubled in the past three decades.[2] An additional 280”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“≥5% weight loss compared to placebo.[29] The odds ratio of developing diabetes was 8.”
BackgroundStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Economic Costs of Diabetes in the U.S. in 2012
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc12-2625 · Cited by 2,163
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · cited 2×
“For patients who are overweight or obese, the Endocrine Society Clinical Practice Guideline [26] recommends weight management before treating comorbidities.”
BackgroundDiabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting
Cade, W. T. (2008) · Physical Therapy · doi:10.2522/ptj.20080008 · Cited by 1,084 · cited 1×
“betes phase.[4,5,7,8] For example, patients with prediabetes”
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Self-citation
Research works printed but not linked: 6
- International Diabetes Federation, 2013, IDF Diabetes Atlas
- Portero McLellan KC, 2014, Ther Clin Risk Manag, 10, 173
- BELVIQ (lorcaserin hydrochloride), 2014, US Prescribing Information
- Nesto R, 2014, Diabetes, 63, A27
- American Diabetes Association, 2010, Diabetes Care, 33
- Alqahtani N, 2013, Int J Prev Med, 4, 1025
Cited by
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
“It also slowed the progression of prediabetes to diabetes and increased the percentage of subjects with prediabetes who reverted to euglycemia, a finding that is associated with a longer prevention of diabetes [82].”
Prediabetes: Why Should We Care?
Zand, A., Ibrahim, K., & Patham, B. (2018) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-14-4-289 · Cited by 113
Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P. H., Wallenstein, S. O. R., & le Roux, C. W. (2022) · Diabetes Care · doi:10.2337/dc21-1785 · Cited by 87
Lorcaserin improves glycemic control via a melanocortin neurocircuit
Burke, L. K., Ogunnowo-Bada, E., Georgescu, T., Cristiano, C., de Morentin, P. B. M., Valencia Torres, L., D'Agostino, G., Riches, C., Heeley, N., Ruan, Y., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.07.004 · Cited by 61
Metadata
- Authors
- Nesto, R., Fain, R., Li, Y., & Shanahan, W.
- Affiliations
- Lahey Hospital and Medical Center (US)
- Eisai (United States) (US)
- Arena Pharmaceuticals (United States) (US)
- Corresponding author
- Nesto, Richard
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2016-05-03
- Volume
- 128
- Issue
- 4
- Pages
- 364-370
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W2344286639
- Cited by
- 20
- References
- 28
- Citations by year
- 2024: 2 · 2022: 2 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 4
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Postgraduate Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Arena Pharmaceuticals, Inc
- Eisai, Inc
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lorcaserin, prediabetes, type 2 diabetes prevention, 5-HT2C receptor agonist, weight loss, glycemic control, HbA1c, fasting blood glucose, obesity, bloom, flowers, weight management, drug safety and efficacy, adverse events, serious adverse events, cardiovascular safety
- MeSH terms
- Adult, Benzazepines, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Prediabetic State, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Disease Progression, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. https://app.cochat.ai/papers/10.1080/00325481.2016.1178590
- The paper
- Nesto, R., Fain, R., Li, Y., & Shanahan, W. (2016). Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. Postgraduate Medicine. https://doi.org/10.1080/00325481.2016.1178590
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.